Information Provided By:
Fly News Breaks for March 2, 2020
Mar 2, 2020 | 07:36 EDT
Raymond James analyst Lawrence Keusch upgraded Masimo to Outperform from Market Perform with an $183 price target. In a research note to investors, Keusch says that with Masimo down around 8% last week, he believes investors should begin to accumulate the shares due to the company's greater insulation from COVID-19 disruption on a relative basis vs. other companies in his hospital supply coverage universe. Although Masimo did not benefit from COVID-19 in China due to limited share, should the virus spread in Europe and the U.S., the company could see a small net positive impact to revenues, Keusch says. He views Masimo as one of the best growth stories in his universe, though he admits that valuation is not inexpensive.
News For MASI From the Last 2 Days
There are no results for your query MASI